MedPath

Efficacy and Safety of Two Doses of HIL-214 in Children

Phase 2
Terminated
Conditions
Gastroenteritis
Interventions
Biological: Placebo
Registration Number
NCT05281094
Lead Sponsor
HilleVax
Brief Summary

This is a randomized, placebo-controlled study that is being done to evaluate the safety and effectiveness of two doses of the HIL-214 vaccine compared to a placebo. The study will enroll 3000 children who will be 5 months of age at the time of the first dose study vaccine. The second dose of study vaccine will be given 28 days after the first dose.

Detailed Description

Noroviruses have emerged as the single most significant cause of gastroenteritis in both middle-high income countries and low resource settings worldwide. Those most at risk of severe illness include the very young, the elderly and immunocompromised individuals. Noroviruses are highly infectious, highly resistant to environmental conditions, and have multiple routes of transmission including person-to-person, food-borne and contaminated surfaces. Noroviruses can cause acute, mild to severe illness characterized by vomiting, diarrhea, fever, dehydration and abdominal pain, representing a significant burden to public health. The clinical presentation in adults and older children is similar. While mortality due to acute gastroenteritis (AGE) caused by norovirus in the pediatric population is rare in industrialized countries, it is more common in developing countries. Although potentially a cause for hospitalization in very young children, there are fewer cases during the first 6 months of life possibly due to the protection offered by maternal antibodies from trans-placental transfer and in breast milk. In addition, norovirus infections have significant socioeconomic impact on hospitals, schools, day care centers and other closed settings. As the burden of rotavirus in children decreases due to successful rotavirus vaccination programs in infants, norovirus infections are increasingly recognized as the primary cause of AGE in many countries around the world.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
3084
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboOne dose of placebo on Day 1 and one dose of placebo between Day 28 and Day 56.
ExperimentalHIL-214One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 28 and Day 56.
Primary Outcome Measures
NameTimeMethod
To Demonstrate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated Only With GI.1 or GII.4 Norovirus Genotypes.The duration of the primary observation period was 6 months starting at 28 days post dose 2.

Time to first occurrence during the primary observation period, of moderate/severe AGE case associated only with GI.1 or GII.4 norovirus genotypes. Vaccine efficacy (VE) is defined as 100% \[1- (λV/λC)\], where λV and λC denote the hazard rates of the primary endpoint AGE case for the HIL 214 and placebo arms, respectively. The primary endpoint AGE case is defined as at least 3 loose or liquid stools OR at least 2 or more episodes of vomiting OR 1 or more loose or liquid stools plus 1 or more vomiting episodes in any 24-hour period. The presence of norovirus in onset stool samples was assessed by RT-PCR and norovirus-positive samples were genotyped by sequencing. Samples that were positive for GI.1 or GII.4 genotypes were further analyzed for the presence of co-pathogens. VE estimates and 95% confidence intervals (CIs) are also reported.

Secondary Outcome Measures
NameTimeMethod
To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated Only With Any Norovirus (GI or GII) Genogroup.The duration of the primary observation period was 6 months starting at 28 days post dose 2.

Time to first occurrence during the primary observation period, of moderate/severe AGE case associated with any (GI or GII) genogroup Vaccine efficacy (VE) is defined as 100% \[1- (λV/λC)\], where λV and λC denote the hazard rates of the primary endpoint AGE case for the HIL 214 and placebo arms, respectively. The endpoint AGE case is defined as at least 3 loose or liquid stools OR at least 2 or more episodes of vomiting OR 1 or more loose or liquid stools plus 1 or more vomiting episodes in any 24-hour period. The presence of norovirus in onset stool samples was assessed by RT-PCR and norovirus positive samples were genogrouped by sequencing. Samples that were positive for GI or GII genogroups were further analyzed for the presence of co-pathogens. Vaccine efficacy (VE) estimates and 95% confidence intervals (CIs) are also reported.

To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated With GI.1 or GII.4 Norovirus Genotypes, Irrespective of Other Gastrointestinal Pathogens.The duration of the primary observation period was 6 months starting at 28 days post dose 2.

Time to first occurrence during the primary observation period\* of moderate/severe AGE case associated with GI.1 or GII.4 norovirus genotypes, irrespective of other gastrointestinal pathogens. Vaccine efficacy (VE) is defined as 100% \[1- (λV/λC)\], where λV and λC denote the hazard rates of the primary endpoint AGE case for the HIL 214 and placebo arms, respectively. The primary endpoint AGE case is defined as at least 3 loose or liquid stools OR at least 2 or more episodes of vomiting OR 1 or more loose or liquid stools plus 1 or more vomiting episodes in any 24-hour period. The presence of norovirus in onset stool samples was assessed by RT-PCR and norovirus-positive samples were genotyped by sequencing.

To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated With Any Norovirus Genogroup (GI or GII), Irrespective of Other Gastrointestinal PathogensThe duration of the primary observation period was 6 months starting at 28 days post dose 2.

Time to first occurrence during the primary observation period of moderate/severe AGE case associated with any norovirus genogroup (GI or GII), irrespective of other gastrointestinal pathogens. Vaccine efficacy (VE) is defined as 100% \[1- (λV/λC)\], where λV and λC denote the hazard rates of the primary endpoint AGE case for the HIL 214 and placebo arms, respectively. The endpoint AGE case is defined as at least 3 loose or liquid stools OR at least 2 or more episodes of vomiting OR 1 or more loose or liquid stools plus 1 or more vomiting episodes in any 24-hour period. The presence of norovirus in onset stool samples was assessed by RT-PCR and norovirus positive samples were genogrouped by sequencing. Vaccine efficacy (VE) estimates and 95% confidence intervals (CIs) are also reported.

Immunogenicity of HIL-214 Compared to PlaceboParticipant reaches 1 year of age

The percentage of participants with a predefined seroresponse (≥4-fold rise in antibody concentration) at up to 56 days post dose 1 (Visit 2), 28 days post dose 2 (Visit 3), and/or at 1 year of age (visit 4) to the GI.1 and GII.4c components of HIL-214 and 95% confidence interval are reported. HBGA-blocking and pan-Ig assays were used for immunogenicity analyses

Safety of HIL-214 Compared to Placebo - Adverse Events (AEs) Leading to Vaccine WithdrawalUp to 28 days after first dose of HIL-214 or placebo.

Percentage of participants with AEs leading to trial vaccine dose withdrawal.

Safety of HIL-214 Compared to Placebo - Adverse Events (AEs) Leading to Trial Withdrawal.From Day 1 to end of the trial/early termination.

Percentage of participants with AEs leading to trial withdrawal.

Safety of HIL-214 Compared to Placebo - Solicited Local Adverse Events (AEs)Up to 7 days after each dose of HIL-214 or placebo.

Percentage of participants with solicited local (injection site) adverse events (AEs) within 7 days of vaccine administration. Assessed AEs include injection site pain, erythema, induration, and swelling.

Safety of HIL-214 Compared to Placebo - Solicited Systemic Adverse Events (AEs)Up to 7 days after each dose of HIL-214 or placebo.

Percentage of participants with solicited systemic AEs within 7 days of vaccine administration. Assessed AEs include drowsiness, irritability/fussiness, loss of appetite, vomiting, and diarrhea.

Trial Locations

Locations (17)

DM Clinical Research

🇺🇸

Houston, Texas, United States

Policlinico Social del Norte

🇨🇴

Bogotá, Distrito Capital, Colombia

Cntro de Estudios en Infectologia Pediatrica (CEIP)

🇨🇴

Cali, Valle Del Cauca, Colombia

Hospital Pediátrico Dr. Hugo Mendoza

🇩🇴

Santo Domingo, Distrito Nacional, Dominican Republic

Hospital General Regional Marcelino Velez Santana

🇩🇴

Santo Domingo, Dominican Republic

CAIMED - Dominican Center for Clinical Studies

🇩🇴

Santo Domingo, Dominican Republic

Clínica Cruz Jiminian

🇩🇴

Santo Domingo, Dominican Republic

Fundacion Dominicana de Perinatologia Pro Bebe

🇩🇴

Santo Domingo, Dominican Republic

Demedica

🇭🇳

San Pedro Sula, Honduras

INVERIME - Inversiones en Investigación Medica

🇭🇳

Tegucigalpa, Honduras

Scroll for more (7 remaining)
DM Clinical Research
🇺🇸Houston, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.